Crohn's disease (CD) and ulcerative colitis (UC) are the major types of chronic inflammatory bowel disease (IBD) characterized by recurring episodes of inflammation of the gastrointestinal tract. Although it is well established that human leukocyte antigen (HLA) is a major risk factor for IBD, it is yet to be determined which HLA alleles or amino acids drive the risks of CD and UC in Asians. To define the roles of HLA for IBD in Asians, we fine-mapped HLA in 12 568 individuals from Korea and Japan (3294 patients with CD, 1522 patients with UC and 7752 controls). We identified that the amino acid position 37 of HLA-DRβ1 plays a key role in the susceptibility to CD (presence of serine being protective, P = 3.6 × 10 −67 , OR = 0.48 [0.45-0.52]). For UC, we confirmed the known association of the haplotype spanning HLA-C * 12:02, HLA-B * 52:01 and HLA-DRB1 * 1502 (P = 1.2 × 10 −28 , OR = 4.01 [3.14 -5.12]).
Introduction
Crohn's disease (CD) and ulcerative colitis (UC) are the two major types of chronic inflammatory bowel disease (IBD) of an unknown etiology (1) . The clinical characteristics of IBD are often notably different between distinct ethnicities (2) . For example, in Western countries, there is no sex-specific predominance and the proportions of CD patients with disease located in the ileum alone, the colon alone and both the ileum and colon are approximately equal. However, in Asians, there is a strong male predominance (1.7:1 to 2.9:1) and the ileocolonic disease alone comprises almost two thirds of CD cases while colonic disease comprises only ∼10% (2) . These clinical differences suggest that there might be heterogeneous genetic factors as well as environmental factors between populations, emphasizing the need for a separate genetic study of IBD for Asians. Indeed, recent genome-wide association studies (GWASs) suggested that there can be Asianspecific genetic components of IBD throughout the genome (3) (4) (5) .
Human leukocyte antigen (HLA) forms the major histocompatibility complex (MHC) that brings antigens to cell surfaces for T-cell responses and is a well-known risk factor for many immune diseases including IBD. Due to the hyper-polymorphic nature of HLA and high cost of typing, an accurate fine-mapping of which alleles or amino acids are driving the risk of diseases has been a challenge. Recently, imputation technology became available, which allowed investigations of HLA alleles and amino acids in large-scale without actually typing HLA (6, 7) . Applications of this technology enabled discoveries of disease-driving amino acids and alleles in a number of immune diseases such as rheumatoid arthritis (8) , type 1 diabetes (9) and psoriasis (10) . A recent European IBD study applied this technology to disentangle the complex associations of HLA in Europeans (11) .
This study found that HLA-DRB1 * 01:03 explains the largest contribution to both CD and UC in Europeans. This allele is not observed in Asians [absent in 1851 Asian samples (12) (13) (14) ].
Previous studies on HLA of IBD in Asians focused on class II HLA alleles. For instance, HLA-DRB1 * 15:02 was shown to be associated with UC in both Japanese (15) (16) (17) and Korean populations (18) . A recent meta-analysis of Japanese IBD genetics reported that HLA-DRB1 * 04:05 increased susceptibility to CD but decreased susceptibility to UC (5) . However, a comprehensive fine-mapping including both HLA alleles and amino acids has not been performed yet in Asians.
The purpose of this study was to investigate which HLA alleles or amino acids drive the HLA associations to CD and UC in Asians. To fine-map MHC for IBD in Asians, we collected 12 568 individuals from Korea and Japan (3294 patients with CD, 1522 patients with UC and 7752 controls), which was the largest collection of samples to date for Asian HLA analysis. We imputed HLA alleles and amino acids of these individuals using a recently developed imputation technology (6) coupled with populationspecific reference panels (12, 13) . We analyzed CD and UC separately to define the role of HLA on each disease in Asians.
Results

CD is associated with DRβ1#37 and DQβ1#57 in Koreans
After HLA imputation (see Materials and Methods), we tested associations between CD disease status and binary markers in MHC using our discovery dataset (1466 CD cases and 1677 controls, typed with Immunochip). We observed that the presence of serine at amino acid position 37 of HLA-DRβ1 was To replicate these associations, we used independent samples (526 CD cases and 3739 controls, typed with Illumina OmniExpress and Omni1-Quad arrays). We performed independent fine-mapping as if this replication dataset were another discovery dataset. If the top signal matches between the two datasets, it would give us confidence on the fine-mapped position. When we fine-mapped associations, the top signal turned out to be the same Ser37 at HLA-DRβ1 [P = 9.1 × 10 −15 , OR = 0.47 (0.39 -0.57)]. Conditioning on DRβ1#37, no association reached the significance threshold (5 × 10 −8 ), but the smallest P-value was observed at Asp57 of HLA-DQβ1 similar to the discovery analysis [P = 2.0 × 10 −6 , OR = 1.44 (1.24 -1.67)]. Therefore, the two positions (DRβ1#37 and DQβ1#57) stood out in both datasets with similar effect sizes.
We then performed a joint analysis of all Korean discovery and replication samples (1992 patients with CD and 5416 controls). Not surprisingly, the top signal was Ser37 at HLA-DRβ1 [P = 1.4 × 10 −42 , OR = 0.45 (0.40-0.51); Fig. 1A ]. We investigated if there was an HLA allele that 'tags' Ser37, in which situation it would be unclear as to which variation was driving the association. However, the most significant HLA alleles either within HLA-DRB1 [HLA-DRB1 * 01; P = 3.8 × 10 −16 , OR = 0.40 (0.32-0.50)] or outside HLA-DRB1 [HLA-DQB1 * 04; P = 9.7 × 10 −19 , OR = 1.69 (1.51-1.90)] were >20 orders of magnitude less significant than Ser37 (Fig. 1B) . This notable difference in P-values supported a hypothesis that this specific amino acid position (DRβ1#37) might be driving the susceptibility to CD in Asians. We performed the amino acid-focused omnibus test and the most significant position was consistently DRβ1#37 (P Omnibus = 2.8 × 10 −59 ) among all positions within the HLA genes tested (Supplementary Material, Table S3 ). Conditioning on DRβ1#37, Asp57 at HLA-DQβ1 was the most significant [P = 7. Table S2 ).
CD association at DRβ1#37 was replicated in Japanese
We sought to examine the consistency of the association at DRβ1#37 for CD in different Asian countries. To this end, we performed a cross-country replication analysis using Japanese samples (1302 CD cases and 2336 controls). We used the recently built Japanese reference panel (N = 908) (12) to impute HLA (see Materials and Methods). We then performed fine-mapping within Japanese individuals. The omnibus test of all amino acid positions in the seven HLA genes showed the strongest association at DRβ1#37 (P Omnibus = 2.9 × 10 −33 , Supplementary Material, Table S3 ), which was precisely the position observed in the Korean analysis. In the binary-marker analysis, as in the Korean analysis, we observed independent signals from both HLA-DRB1 and DQB1 (Supplementary Material, Fig. S1 ). The top signal was at the SNP rs4713586 in HLA-DQB1 [P = 9.5 × 10 −33 , OR = 2.00 (1.78-2.24)]. This SNP was in linkage disequilibrium (LD) (r 2 = 0.99) with HLA-DQB1 * 04 [P = 9.8 × 10 −33 , OR = 2.00
(1.78-2.25), Supplementary Material, Table S4 ], which was equivalent to Leu56 in this dataset. When we conditioned on rs4713586, a secondary signal was observed at DRβ1#70 [presence of glutamine, P = 2.2 × 10 −15 , OR = 0.64 (0.57-0.71)]. After further conditioning on the top DRB1 signal (DRβ1#70) in the Japanese data, no other marker proved significant (P > 5 × 10 −8 ). Thus, although Ser37 of HLA-DRβ1 was the top signal in the Korean binary/omnibus test analysis and the Japanese omnibus test analysis, it was not the top signal in the Japanese binary test analysis. However, Ser37 of HLA-DRβ1 was highly significant (P = 5.9 × 10 −27 and 2.6 × 10 −13 before and after conditioning on rs4713586, respectively) and the effect size was consistent [OR = 0.52 (0.46 -0.59), Table 1 ]. We further examined the effect sizes of all five amino acid residues positioned at DRβ1#37 and compared them between different datasets. The effect sizes were highly concordant between Koreans and Japanese (correlation of log OR = 0.89) but less concordant between Koreans and Europeans (correlation of log OR = 0.55) (Fig. 1C) . Overall, the results supported that the CD associations at DRβ1#37 were consistent between the two Asian countries (Table 1) . To combine all data from both countries, we performed a meta-analysis comprising a total of 3294 CD cases and 7752 Table S5 ) and the omnibus test (P Omnibus = 1.7 × 10 −89 , Supplementary Material, Table S3 and Table S7 and Fig. S3 ). When we compared the observed effect sizes of amino acid residues at DRβ1#13 in our dataset to the previously reported effect sizes of those in Europeans (11), there was a positive but small correlation (correlation of log OR = 0.18; Fig. 2C 
Amino acid positions in 3D molecule structures
We investigated the locations of the amino acid positions DRβ1#37, DQβ1#57 and DRβ1#13 in the 3D molecular structures of the MHC class II complex. We downloaded the protein structures of HLA-DR and DQ from Protein Data Bank (PDB) and mapped the amino acid positions (Fig. 3A and B, see Materials and Methods). Because HLA-DR and DQ have conserved structures, we superposed the two (Fig. 3C ). As expected, the folding of the two proteins was similar (the root-meansquare deviation was only 1.13 Å after fitting based on the alpha carbon backbone and 1.07 Å after fitting based on the secondary structure). The two positions driving CD (DRβ1#37 and DQβ1#57) were proximal (9.3 Å) to each other in the superposed structure. However, a closer analysis revealed that their roles might be different. DQβ1#57 was close to the antigen peptide (6.7 Å). The R group of amino acids in this position faced the antigen peptide, potentially implying a direct interaction. Conversely, DRβ1#37 was on the beta sheet at the rear side of the antigen binding groove, which appears to be too distant (12.6 Å) from the antigen peptide to make a direct interaction. We observed that DRβ1#37 was physically very close to the alpha helix trim structure of the binding groove (4.9 Å, Supplementary Material, Fig. S4 ). When we examined all 35 positions (residue from 14 -48) in the binding groove-facing beta sheets of HLA-DRβ1, position 37 had the shortest distance to the alpha helix trims of the binding groove. Therefore, bulky aromatic residues (such as Tyr and Phe, which showed the highest OR in Table 1 ) placed at this position might potentially affect the shape of the groove structure. The UC-associated positions (DRβ1#13 and 11, Fig. 3D ) were close to the antigen peptide (7.5 Å for both 13 and 11, Supplementary Material, Fig. S4 ), similar to DQβ1#57.
Discussion
This study was the first attempt to comprehensively define the HLA alleles and amino acids posing risks for IBD in Asians, using the largest Asian sample for HLA analysis to date. This study was made possible by the recently developed HLA imputation technology (6), which allowed for HLA fine-mapping without actually typing HLA. Our conclusion was that DRβ1#37 is a major susceptibility factor for CD in Asians. In UC, we discovered the previously known risk factor (haplotype spanning C * 12:02-B * 52:01-DRB1 * 15:02).
Our results are consistent with previous observations that CD displays heterogeneity in genetic architectures among ethnicities (3, 4) . The strongest signal in our Asian HLA analysis was Ser37 of DRβ1 [P = 3.6 × 10 −67 , OR = 0.48 (0.45-0.52)], but it only showed a P-value of 7.1 × 10 −4 [OR = 0.95 (0.92-0.98)] in the largest European HLA study (11) . Although this P-value appears to be nominally significant, it was much less significant compared to their top signal HLA-DRB1 * 01:03 [P = 3 × 10 −62 , OR = 2.53 (2.25-2.85)]. We examined if the heterogeneous results between ethnicities were due to different proportions of CD subtypes (2). To assess the possible role of Ser37 of DRβ1 to ileal CD, ileocolonic CD and colonic CD, we examined the effect size of Ser37 of DRβ1 in each of our CD subtypes: ileum, ileocolon and colon. The effect sizes were not significantly different among subtypes (Supplementary Material, Fig. S7 ), suggesting that differences in subtype proportions may not be the major cause of the observed heterogeneity. As for the European top signal (HLA-DRB1 * 01:03), this allele was not present in any of the three existing Asian HLA reference panels (sampled from general population, combined N = 1851) (12) (13) (14) . Thus, this allele might be absent in Asians. Since N = 1851 samples can capture alleles of frequency >0.08% at least once by 95% chance, DRB1 * 01:03 must be extremely rare even if it exists in Asians. Given our case/control study size, the power to detect an allele of frequency 0.08% and of OR = 2.53 was < 1%. Thus, our association results would not change much even if DRB1 * 01:03 exists in our sample.
Between the same Asian countries, genetic structures of CD were overall concordant as expected, albeit with slight differences. The top amino acid position in the omnibus tests was exactly concordant as DRβ1#37. Although the exact top signals in the binary analysis were not the same between the two countries (Supplementary Material, Fig. S1 ), the top signals in one study were significant in another study. The top signals from Koreans (DRβ1#37 and DQβ1#57) were highly significant in the Japanese population [Ser37 at HLA-DRβ1 was P = 5.9 × 10 −27 , OR = 0.52 (0.46-0.59) and Asp57 at HLA-DQβ1 was P = 2.0 × 10 −13 , OR = 1.58 (1.39-1.79)], which explains why these were pronounced as top signals in the meta-analysis. The top signals from the Japanese population (rs4713586/DQβ1#56 and DRβ1#70) were also significant in Koreans [Leu#56 at HLA-DQB1 was P = 9.7 × 10 −19 , OR = 1.69 (1.51-1.90) and Gln#70 at HLA-DRB1 was P = 1.6 × 10 −14 , OR = 0.72 (0.66-0.78)]. In contrast to CD, for UC, the top signal (haplotype spanning C * 12:02, B * 52:01 and DRB1 * 15:02) was a known risk factor for both Asians (17) and Europeans (11) . Previously reported effect sizes were smaller [C * 12:02; OR = 2.24 (1.99-2.52) in Europeans (11) and OR = 2.57 (2.09-3.17) in Japanese (17) ] than that of our study [OR = 3.75 (2.97-4.72)], but the directions were the same (Supplementary Material, Fig. S6 ). Thus, association at this haplotype appears to be shared between ethnicities. Given the tight LD among the three alleles and indistinguishably similar P-values, it was difficult to distinguish which allele was driving the signal. We note that in previous studies (11, 17) , class I alleles (C * 15:02 and B * 52:01) showed smaller P-values than DRB1 * 15:02 by a moderate degree. This haplotype is also known for its association with CD in the opposing direction (17) . Since DRB1 * 15:02 includes serine at position 37, which was our top signal in CD, we examined whether the opposing effect of this haplotype is due to this amino acid. When we conditioned on Ser37 of DRβ1, the association of DRB1 * 15:02 with CD indeed diminished (P = 6.2 × 10 −5 , OR = 0.60 became P = 0.10, OR = 1.26 in Korean data). However, its association with UC did not disappear (P = 6.6 × 10 −21 , OR = 3.04 after conditioning). Thus, the protective effect of this haplotype on CD can possibly be explained by Ser37 of DRβ1 but not the risk effect on UC. After conditioning on this haplotype, the secondary signal in UC, DRβ1#13 and DRβ1#11 was also consistent with the result of a European study that found this position as the top signal (19) . The largest European HLA IBD study (11) suggested, however, that DRβ1#11 alone could not explain the associations at HLA-DRB1 in a more parsimonious way than the HLA alleles. We expect that further investigations will be needed to confirm the validity of the association at this position.
Our results supported a hypothesis that CD and UC have completely different MHC architectures in Asians. Fine-mapping each IBD subtype gave us distinct HLA markers as the top signals (DRβ1#37 and DQβ1#57 for CD and C * 12:02-B * 52:01-DRB1 * 15:02 haplotype and DRβ1#13 for UC). We analyzed whether or not the top markers in CD showed associations with UC and vice versa. The markers were often nominally significant in the other subtype but still much less significant than the top markers of the other subtypes (Supplementary Material, Fig. S5 ). Because the complicated LD structure in MHC can easily induce indirect associations, we cannot prematurely conclude that these markers have shared effects within the two subtypes; this observation was in line with the European analysis (11) where many associ- ated alleles showed heterogeneous effect sizes between UC and CD, after excluding the shared top signal at HLA-DRB1 * 01:03, which is possibly absent in Asians.
HLA fine-mapping analysis based on imputation can have limitations. First, we can only investigate on genes that are present in the reference panel. Although we focused on six (in Koreans) and seven (in Japanese) class I and II genes that were present in the panels, there exist numerous genes in MHC that were not included in this analysis. Particularly, the European study reported associations at HLA-DQA1 (11), but we were not able to investigate on this gene due to missing in the panels. Second, imputation inaccuracy may affect the accuracy of finemapping. Third, it is often not clear whether amino acids or HLA alleles are driving the risk. Associations at amino acids can be interpreted as alterations of chemical properties of proteins caused by amino acid variations. In contrast, associations at HLA alleles can be interpreted as simultaneous changes of multiple amino acid positions that can interact with each other or the consequence of unknown nearby components tagged by the haplotype. In previous HLA analyses of some phenotypes, amino acids turned out to be driving the associations (8, 9, 20) , while for some other phenotypes, HLA alleles were driving the risk (10) . In our analysis of CD in Asians, the top signal (Ser37 at DRβ1) was > 20 orders of magnitude more significant than the most significant HLA alleles (Fig. 1A) . Thus, we concluded that this amino acid position could play a key role in Asians.
Imputation accuracy can be affected by the size of reference panel. In our analysis, we used the Korean panel (13) for Korean analysis and the Japanese panel (12) for Japanese analysis. Another possible strategy could be merging the two panels and using it for both. Although we could not try this due to logistical reasons, we wanted to examine if the size of reference panel could affect our results. To this end, we merged the Korean panel and the Pan-Asian panel (14) using the merging tool (21) and re-imputed the Korean dataset. The allele predictions were overall similar using either the single panel or the merged panel (Supplementary Material, Table S8 ), where the discordance rate of each HLA gene was smaller than the known error rate of SNP2HLA in Koreans (13) . Moreover, the top associations did not change [Ser of DRβ1#37 in CD (P = 1.37 × 10 −42 and OR = 0.45) and DRB1 * 15:02 in UC (P = 2.1 × 10 −30 and OR = 3.44)], showing that our results have not been much affected by the imputation errors caused by the limited reference panel size.
To the best of our knowledge, DRβ1#37 has not been reported as a major risk factor for other immune diseases. In contrast, DQβ1#57 was well known for its risk of type 1 diabetes (9, 22) , whereas DRβ1#13/11 was well known for its risk of rheumatoid arthritis (8, 23) . Nevertheless, the mechanism of these observed associations to diseases is largely unknown. Our structural analysis showed that DQβ1#57 and DRβ1#13/11 were close to the antigen peptides, and DRβ1#37 was in a position where a bulky residue could affect the shape of the binding groove. It is established that DQβ1#57 can also have an influence over the shape of the groove, wherein aspartate can give rise to a closed groove and alanine or serine is more 'relaxed' (24) . We expect that exactly how these identified HLA variations exert effects on IBD will warrant further investigations.
Materials and Methods
Samples
Korean discovery and replication sample data. In the Korean dataset, a total of 3514 patients with IBD (1992 CD cases and 1522 UC cases) and 5416 unrelated healthy controls were included.
All patients with IBD were recruited from the IBD Clinic of Asan Medical Center, Seoul, Korea. IBD was diagnosed based on standard clinical, radiologic, endoscopic and histopathologic criteria (25) . Patients with indeterminate colitis were excluded from the study. In the discovery stage, we combined (1) our previously reported Immunochip data from 1419 patients with IBD (716 CD and 703 UC) and 1185 healthy controls with (2) newly typed Immunochip II data from an additional 1356 patients with IBD (750 CD and 748 UC) and 492 healthy controls. We then utilized our previously reported GWAS data from 597 patients with IBD (526 CD and 71 UC) and 3739 healthy controls (the numbers reported excluded overlapping individuals) (26) . These samples were genotyped using three different chips (Human Omni1-Quad BeadChip, Human OmniExpress BeadChip and Infinium OmniExpressExome BeadChip), in which overlapping SNPs were used. For CD, we utilized these GWAS samples as replication data. For UC, because we only had 71 cases remaining in the GWAS data after removing any overlaps, we merged them into the discovery analysis. Details of the clinical characteristics of the Korean individuals are given in Supplementary Material, Table S1 .
Japanese sample collection. We enrolled 1302 CD cases and 2336 controls for the Japanese population. All cases with CD were recruited at the Tokyo Yamate Medical Center, Toho University, Sakura Medical Center, Sapporo Kosei General Hospital, as well as Kyushu University and 16 other affiliated hospitals. DNA samples of controls were obtained from Biobank Japan (27, 28) . All of these samples were genotyped by Immunochip and included in our previous trans-ethnic study (3) . PCA outliers from the Japanese cluster and any closely related samples estimated using identity by state were excluded from the analysis. For the analysis of the MHC region, we selected samples according to the following inclusion criteria: (1) samples with a call rate of ≥0.99 in the MHC region and (2) Japanese samples that were included in the Hondo cluster (29) estimated by PCA. Subjects included in the Japanese reference panel were not included in the association analysis.
Statistical analyses
HLA imputation. We imputed cases and controls together for binary markers defined for classical HLA alleles, amino acids and SNPs using SNP2HLA (v1.0.3) with default parameters (6) . The binary markers represent the presence and absence of each allele or amino acid residue as well as each group of amino acid residues. For Korean datasets, we used a Korean panel (N = 413) that was shown to be accurate for imputing HLA in Koreans (13) . This panel included data for HLA-A, B, C, DRB1, DQB1 and DPB1. We extended the panel to include the binary markers representing groups of amino acid residues. The final panel included 6586 binary markers within Chr6:29-34 Mb. We performed imputation separately for three Korean cohorts typed with different technologies (Immunochip I, Immunochip II and GWAS chip; Supplementary Material, Table S1 ). For the Japanese dataset, we used a Japanese panel (N = 908) that was shown to be accurate for imputing HLA in a Japanese cohort (12) . This panel included 11 854 binary markers defined for HLA-A, B, C, DRB1, DQB1, DPA1 and DPB1.
Statistical framework for association testing. We analyzed associations by testing the correlations between the disease status (coded as 1 and 0 for cases and controls) and imputed genotypes of each of the binary markers using a logistic regression model
where k is the marker tested, g k,i is the dosage of k at individual i and β k is the effect of the marker. Our null hypothesis was that the marker has no effect (β k = 0). We performed this test using PLINK v1.07 (http://zzz.bwh.harvard.edu/plink/). To account for multiple testing, we conservatively used the significance threshold 5 × 10 −8 . After we identified a statistically significant marker, we performed a conditional analysis by including the marker as a covariate in the logistic regression. When we conditioned on a specific amino acid position, we conditioned on all residues at that position (except for one residue, to avoid collinearity) in order to remove all effects associated to that position conservatively. Because our discovery dataset comprised two cohorts typed with different platforms (Immunochip and Immunochip2), we included a binary covariate indicating the cohorts.
Joint analysis and meta-analysis.
To combine the results of the Korean discovery and Korean replication analyses in a joint analysis, we merged the genotype data and included a covariate indicating the discovery and replication details. To combine the results of the Korean joint analysis and the Japanese analysis in a meta-analysis, we combined the summary statistics using a fixed effects model (inverse variance-weighted average) using our in-house R script. Only the overlapping markers of the Korean and Japanese datasets were used in meta-analysis, because the marker sets were not completely identical due to differing allele frequencies and the use of different reference panels.
Omnibus test. We performed the amino acid-focused omnibus test. Given an amino acid position with K different residues, we assessed the deviance of the model when we put K-1 variables representing the residue differences compared to the null model. The deviance difference was then compared to the chi-square distribution with K-1 degrees of freedom to obtain an omnibus test P-value, using our in-house R script. To combine the Korean and Japanese omnibus test results, we used Fisher's method for combining P-values using R.
3D structure analysis
We downloaded protein structures of HLA-DR (PDB id:3pd0) and DQ (PDB id:1jk8) from the PDB (http://www.rcsb.org/pdb) and visualized them using PyMOL (version 1.3). Superposition analysis was performed using WinCoot (version 0.8.1, University of Oxford). We focused on the physical positions and the distances between the amino acids because surface hydrophobicity or electropotential analysis can largely depend on specific sequences. For physical distances, we measured the distances between alpha carbons of amino acids so that the measures could be independent of the residues at the positions.
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